Project Grant R50CA305079
Award Date 9/8/25
Completion Date 8/31/30
Dollars Obligated $198K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Pennsylvania, USA
Similar Awards
- This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to The Trustees of the University of Pennsylvania to support the development and implementation of NCI-sponsored clinical trials for rare cancers. The $122,610 award, which began in August 2025, aims to: Assist junior and mid-career oncology faculty in developing investigator-initiated studies, and Develop a program within the National Clinical Trials Network (NCTN) to design...
- This federal Project Grant award, funded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395), supports efforts by a Columbia University researcher to develop and implement NCI-sponsored cancer clinical trials at the NCI-designated Herbert Irving Comprehensive Cancer Center (HICCC). The $193,926 award, with a project period from September 1, 2025 to August 31, 2030, will enable the researcher to: (1) develop novel HICCC investigator-led trials for...
- The U.S. National Cancer Institute (NCI) has awarded a $3,480,276 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Seattle Children's Hospital, doing business as Seattle Children's Research Institute. The funding will support a 4-year research initiative to systematically uncover the genomic heterogeneity of pediatric and adolescent/young adult Philadelphia chromosome-positive (Ph+) and ABL-class Ph-like acute lymphoblastic leukemia (ALL). The overarching goals are to...
- This Project Grant award from the National Institutes of Health's (NIH) National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $901,205 to The Children's Hospital Corporation (doing business as Boston Children's Hospital) to conduct genome-wide studies examining how tumor immune editing in early-stage cancers leads to immune evasion and suppression. The research aims to identify key genes, pathways, and processes that are epigenetically repressed during early tumor...
- This federal Project Grant award of $109,076.00, awarded by the National Cancer Institute (CFDA 93.398 Cancer Research Manpower program) on December 17, 2025, supports research to immuno-modulate diffuse midline glioma, an aggressive pediatric brain tumor, through epigenetic reprogramming. The project, led by the University of Miami, aims to advance scientific understanding and develop new treatment approaches for this deadly disease. The 4-year project period runs through September 1, 2029. The...
- This Cooperative Agreement award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $481,052 to the Research Institute at Nationwide Children's Hospital to develop a preclinical/clinical pipeline to rapidly test new therapies for a deadly form of pediatric rhabdomyosarcoma (RMS) driven by mutant MYOD1. The primary goal is to identify effective treatments, including PI3K-targeted therapies, for this almost universally lethal malignancy by leveraging...
- This Project Grant award of $742,391 from the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395) supports research conducted by Tufts University School of Medicine to develop an in vivo model system that can recapitulate the development and evolution of clonal hematopoiesis (CH) during aging, tumorigenesis, and cancer treatment. CH is a premalignant condition associated with increased risk of hematologic malignancies, particularly in cancer patients undergoing...
- This Project Grant award for $289,937.00 from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) supports a clinical trial evaluating the safety and antitumor activity of B7-H3-CAR T cell therapy in combination with hypofractionated radiation therapy for pediatric patients with relapsed/refractory sarcomas. The award recipient, St. Jude Children's Research Hospital Inc., will oversee the conduct of the clinical trial and implement embedded correlative studies to assess the in...
- This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) provides $290,017.00 to St. Jude Children's Research Hospital Inc. to investigate the cell state hierarchy and transcriptional/epigenetic determinants of therapy-resistant progenitor-like cells in fusion-negative rhabdomyosarcoma (FN-RMS), a type of pediatric soft tissue sarcoma. The award will support computational and experimental research approaches, including single-cell RNA sequencing,...
- This Project Grant award of $562,869, provided by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research program (CFDA 93.393), supports research to define the role of chromosome 17q gain in the malignancy of neuroblastoma, the most common pediatric extracranial solid tumor. The principal investigators at Children's Hospital Los Angeles will use a human stem cell model of neuroblastoma to: 1) compare the tumorigenic potential of 17q gain and MYCN in immature cells...